Delee
Company

Last deal

Amount

Equity Crowdfunding

Stage

01.10.2022

Date

4

all rounds

$2.4M

Total amount

General

About Company
Delee developed CytoCatch™ for early cancer detection and treatment monitoring.

Industry

Sector :

Subsector :

Keywords :

founded date

01.11.2016

Number of employees

Company Type

For Profit

Last funding type

Equity Crowdfunding

IPO status

Private

Description

CytoCatch™ is an innovative medical device that isolates and analyzes circulating tumor cells (CTCs) from blood samples. This technology, consisting of an isolation platform and an imaging system, automates the necessary steps to process the sample and captures CTCs for analysis. The captured cells can be used for molecular analysis to assess the genetic characteristics of the CTCs. CytoCatch™ has a wide range of applications in cancer diagnosis, patient monitoring, and personalized care. Delee, founded in 2017 and based in Sunnyvale, California, aims to revolutionize cancer management with their advanced blood test device.
Contacts

Phone number

Social url